CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe?

Journal Article Corrected proof CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe? Get access Emma F Magavern, Emma F Magavern William Harvey Research Institute, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK Corresponding author. Tel: +44 (0) 20 7882 8808, Email: e.magavern@qmul.ac.uk https://orcid.org/0000-0003-0699-6411 Search for other works by this author on: Oxford Academic Google Scholar John H McDermott, John H McDermott Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester M13 9PL, UKDivision of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester M13 9NT, UK Search for other works by this author on: Oxford Academic Google Scholar Mark J Caulfield, Mark J Caulfield William Harvey Research Institute, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK Search for other works by this author on: Oxford Academic Google Scholar William G Newman William G Newman Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester M13 9PL, UKDivision of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester M13 9NT, UK Search for other works by this author on: Oxford Academic Google Scholar European Heart Journal - Cardiovascular Pharmacotherapy, pvae040, https://doi.org/10.1093/ehjcvp/pvae040 Published: 23 August 2024 Article history Received: 21 February 2024 Revision received: 11 April 2024 Accepted: 17 May 2024 Corrected and typeset: 23 August 2024 Published: 23 August 2024